M&T Bank Corp Makes New $74,000 Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

M&T Bank Corp bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,939 shares of the company’s stock, valued at approximately $74,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of GDRX. Point72 Asset Management L.P. bought a new position in GoodRx in the 3rd quarter worth about $11,295,000. Rubric Capital Management LP grew its position in GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter worth about $5,675,000. Pier Capital LLC bought a new position in GoodRx in the 3rd quarter worth about $3,259,000. Finally, Barclays PLC grew its position in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 1.1 %

GDRX stock opened at $4.42 on Friday. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The firm has a market cap of $1.70 billion, a PE ratio of -147.33, a P/E/G ratio of 2.46 and a beta of 1.25. The firm has a 50 day simple moving average of $4.72 and a 200 day simple moving average of $5.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Analysts Set New Price Targets

GDRX has been the subject of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Citigroup decreased their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a report on Friday, January 10th. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Morgan Stanley decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Finally, Mizuho initiated coverage on shares of GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.